ProCE Banner Activity

NICHD P1081: Improved Virologic Suppression at Delivery With RAL- vs EFV-Based ART in Pregnant Women With HIV Infection

Slideset Download
Conference Coverage
First large randomized study of raltegravir vs efavirenz in pregnant women finds improved virologic suppression at delivery in women receiving raltegravir, particularly when initiating ART after 28 weeks of gestation.

Released: March 07, 2019

Expiration: March 05, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare